Clinical Benefits of 7 Years of Treatment with Omalizumab in Severe Uncontrolled Asthmatics
Journal of Asthma, 05/06/2011Pace E et al.
Long–term treatment with omalizumab improves asthmatic clinical outcomes in severe asthmatics.
7 severe allergic asthmatic patients who were treated for 7 years with add–on omalizumab.
Number of exacerbations, use of antibiotics, additional asthma medications (systemic steroids, nebulized steroids and bronchodilators), and spirometry were analyzed before and after omalizumab treatment.
Omalizumab was well tolerated by all the studied patients.
It improved FEV1 and FEV1//FVC ratio and reduced symptom score, asthma exacerbations, use of antibiotics, and use of nebulized steroids, bronchodilators, and oral corticosteroids.
These effects were evident after 4 years of treatment and more pronounced after 7 years of treatment.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.